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Background: Within Europe many guidelines exist regarding the genetic testing 
of minors. Predictive and presymptomatic genetic testing of minors is 
recommended for disorders for which medical intervention= preventive 
measures exist, and for which early detection improves future medical health. 
Aim: This study, which is part of the larger 5th EU-framework ‘‘genetic 
education’’ (GenEd) study, aimed to evaluate the self-reported responses of 
nongenetic health-care providers in five different EU countries (Germany, 
France, Sweden, the United Kingdom, and the Netherlands) when confronted 
with a parent requesting presymptomatic testing on a minor child for a treatable 
disease. Methods: A cross-sectional study design using postal, structured 
scenariobased questionnaires that were sent to 8129 general practitioners (GPs) 
and pediatricians, between July 2004 and October 2004, addressing self-
reported management of a genetic case for which early medical intervention 
during childhood is beneficial, involving a minor. Results: Most practitioners 
agreed on testing the oldest child, aged 12 years (81.5% for GPs and 87.2% for 
pediatricians), and not testing the youngest child, aged 6 months (72.6% for GPs 
and 61.3% for pediatricians). After multivariate adjustment there were statistical 
differences between countries in recommending a genetic test for the child at the 
age of 8 years. Pediatricians in France (50%) and Germany (58%) would 
recommend a test, whereas in the United Kingdom (22%), Sweden (30%), and 
the Netherlands (32%) they would not. Conclusion: Even though 
presymptomatic genetic testing in minors is recommended for disorders for 
which medical intervention exists, EU physicians are uncertain at what age 
starting to do so in young children. 
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INTRODUCTION  
Genetic testing of minors is a delicate matter and therefore treated with even more 
caution than adult genetic testing. Within Europe there is no common policy with 
regard to genetic testing of minors. Genetic testing of minors can be divided into 
three categories: symptomatic diagnostic testing, predictive and presymptomatic 
diagnostic testing, and carrier testing. 
Symptomatic diagnostic testing is done to diagnose a specific disorder in an 
individual and is generally recommended as part of routine medical care since health 
improves with treatment or early diagnosis (e.g., genetic testing for cystic fibrosis). 
Still, once a diagnosis is made, this has implications not only for the affected child, 
but also for the parents, and other relatives in terms of recurrence risk. 
In contrast to symptomatic diagnostic genetic testing, carrier testing is not 
recommended during childhood (Borry et al., 2005). Ideally, it should be deferred 
until the child him- or herself is able to give proper informed consent. National legal 
regulations differ in regard to the question when a child has the full right to give his 
or her autonomous consent (De Lourdes et al., 2003), but usually this is not before 
the age of 18. Between the existing guidelines there is some disagreement on the role 
of the parents, psychological benefit, and release of information. Further, it is not 
clear whether postponing carrier testing is always in the child’s best interest (Wertz 
et al., 1994; Clarke and Flinter, 1996). It is known that the majority of both carrier 
and noncarrier women in relation to X-linked severe combined immunodeficiency 
retrospectively reported that they wished they had been tested before the age of 18 to 
provide time to develop positive coping mechanisms and to adjust reproductive 
planning (Fanos et al., 2001). Predictive and presymptomatic genetic testing provides 
at-risk individuals with the opportunity to learn whether or not they have inherited a 
deleterious gene that will cause a health problem later in life, inevitably 
(presymptomatic) or with a substantially increased risk (predictive testing). Borry et 
al. (2006b) retrieved 27 guidelines and position papers that explicitly addressed 
predictive and presymptomatic genetic testing of minors in general (not disease 
specific), and were written in English (originally, or translated into English by the 
guideline developers). There were 14 guidelines from Europe (the United Kingdom 
[4], Germany [3], France [2], Italy, Switzerland, Belgium, and Denmark), including 
one EU guideline (European Societies of Human Genetics, 2006). 
Presymptomatic genetic testing in minors is recommended only for childhood onset 
disorders for which medical intervention or preventive measures exists, and in which 
early detection improves future medical health (Ross and Moon, 2000; Borry et al., 
2005, 2006b). The age at which such testing should occur is dependent upon the age 
at which the child is likely to benefit from early medical intervention; this differs 
between disorders. Familial adenomatous polyposis (FAP) is one such genetic 
disorder. Clinical geneticists recommend presymptomatic genetic testing of minors 
for FAP. Those who carry the affected gene should be screened (by sigmoidoscopy) 
every 1–2 years beginning at the age of 10–12 years (Burt, 2000). Another such 
disease is hypertrophic cardiomyopathy (HCM), for which early medical intervention 
for those who carry the mutated gene also is recommended from the age of 10–12 
years (Maron et al., 2003). 
In the absence of clear medical benefit there was some disagreement between 
guidelines on whether or not the child should be tested in its own best interest. Some 
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guidelines stated that testing should be postponed until the child was old enough to 
decide for him- or herself, but it was not clear at what age this could be expected. 
Other guidelines stated that the parents should know what is in the child’s best 
interest (socially or psychologically). Further the concept of best interest itself 
remained unclear. Finally, there was some disagreement on testing for late-onset 
diseases (Borry et al., 2006b). However, presymptomatic genetic testing is not 
recommended for late-onset disorders for which no medical treatment is available 
(e.g., Huntington Disease) (Bloch and Hayden, 1990; McConkie-Rosell and 
Spiridigliozzi, 2004). 
In summary, there appears to be a consensus about diagnostic genetic testing of 
minors, about postponing carrier testing if possible, and about predictive and 
presymptomatic testing in minors, which is recommended only in circumstances 
where a clear medical benefit to the child can be demonstrated (Ross and Moon, 
2000; McConkie-Rosell and Spiridigliozzi, 2004; Borry et al., 2006a, 2006b). In 
spite of the high degree of consensus that exists regarding genetic testing of minors, 
there is still reason to doubt the usefulness of the existing guidelines in daily health-
care practice, even in situations where there is clear medical benefit for the child. It 
can be difficult to determine the timing for testing for childhood onset diseases, to 
determine the age at which the child is competent to decide for him- or herself, to 
determine psychological benefit or what is in the child’s best interest. This study 
aims to explore how nongenetic health-care providers would react when confronted 
with a parent requesting presymptomatic genetic testing on a minor child for a 
treatable disease. 
The present study is part of a larger 5th EU-framework study in which genetic 
education (GenEd) for nongenetic health-care providers was investigated in two 
phases: Phase I of the GenEd project has provided evidence of the current policies 
relating to GenEd initially across five European countries with input from another six 
countries (Challen et al., 2005, 2006; Harris et al., 2006; Henriksson and 
Kristoffersson, 2006; Julian-Reynier and Arnaud, 2006; Plass et al., 2006; Schmidtke 
et al., 2006); Phase II aimed to clarify professional needs by consulting nongeneticist 
health professionals ( Julian-Reynier et al., 2008). 
It is hoped to improve patient care by facilitating the appropriate use of genetic 
information within clinical practice. As a part of this study, we assessed the self-
reported responses of nongenetic health-care providers (general practitioners [GPs] 
and pediatricians) in five different EU countries (France, Germany, 
theUnitedKingdom, Sweden, and theNetherlands), presenting them a scenario of a 




Postal, structured questionnaire using a cross-sectional study design was used. The 
questionnaire was developed in English by a multidisciplinary team from all five 
countries and piloted among English-speaking health professionals in the target 
groups. Piloting in each country was a two-step process. First, the final English 
version of the questionnaire was discussed with small samples of each group of 
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medical doctors (two or three doctors) in each country or with their representatives 
(Germany). At this stage corrections were carried out to better adapt the English 
version to every health-care system and to help to avoid genetic slang and 
misunderstandings. Second, after the translation process (translation and back-
translation) and for piloting of the national versions, two or three physicians per 
specialty in each country were asked to fill out the questionnaire and to make 
remarks during this process. At this stage the remarks made mainly concerned 
typographical errors and improved wording of the questions. After postpilot 
amendments, translation and back-translation was undertaken into the four non- 
English languages to ensure consistency. 
Procedure and sample 
 In the five countries (France, Germany, the United Kingdom, Sweden, and the 
Netherlands) questionnaires were sent that contained a scenario relating to a genetic 
condition (see Appendix). These were sent out to 4244 GPs and 3885 pediatricians 
between July 2004 and October 2004. Subsequent questions addressed practitioners’ 
self-reported responses to the scenario. The scenarios differed for GPs and 
pediatricians, to make the scenarios more applicable in their practice. The clinical 
scenario was chosen as one that could have resonance for clinicians within the 
specialty, even if it was a condition seen rarely. The conditions identified were HCM 
for GPs and FAP for pediatricians, as they both represent diseases where early 
medical intervention could be suggested at around 10 years, but rarely before, raising 
the issue of treatability or prevention at a young age. 
The samples were randomly selected in each country, except for the sample of 
pediatricians in the Netherlands and Sweden. The number of pediatricians in these 
countries was too small to select a sample; thus, questionnaires were sent to all Dutch 
and Swedish pediatricians. 
A brief postal reminder was sent within 2 weeks, and a second reminder, including 
the questionnaire, was sent after 1 month. Respondents in France, Germany, Sweden, 
and the Netherlands were offered an incentive of 10 euros ($14), and £5 ($10) in the 
United Kingdom. In some countries the nonresponding GPs received a third 
reminder by mail (the United Kingdom) or phone (France) because of the lower 
response rate of GPs. For this reason the incentive for GPs was increased in the 
United Kingdom to £10 ($20). 
Measures  
The questions that were asked regarding the scenarios presented were similar for GPs 
and pediatricians, and were posed separately for each child that was mentioned in the 
scenario. Thus, GPs had to answer the questions solely for Melanie (12 years) and 
Tom (6 months), whereas the pediatricians also had to consider Catherine (8 years). 
Respondents were asked to assume that a mutation had been discovered in the parent 
and were asked to rate their likelihood of testing Melanie, Tom, and Catherine 
(pediatricians only) on a four-point scale: definitely not, probably not, probably yes, 
or definitely yes. They were then asked to describe their reasoning for testing or not 
testing each child. The four-option tick boxes for testing (probably yes or definitely 
yes) were as follows: ‘‘I would test this child to plan early medical care’’; ‘‘I would 
test this child to relieve its parent’s uncertainty’’; ‘‘I would test this child since it is 
old enough to understand the implications’’; ‘‘I would test this child for other 
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reasons.’’ The three-option tick boxes for not testing (probably not or definitely not) 
were as follows: ‘‘I would not test this child as the child is too young to plan 
adequate medical care’’; ‘‘I would not test this child as the child is not old enough to 
understand the implications’’; ‘‘I would not test this child for other reasons.’’ Unless 
otherwise stated, for each question, only one box could be ticked. Further, 
demographic variables were asked, for example, sex, age, and work experience. Data 
were entered by scanning using SNAP7 software with operator checking for negative 
answers and double-ticked answers. 
Analyses  
All analyses were performed using SPSS 12.0 for Windows. 
To identify variables associated with the intention to test or not to test each child 
mentioned in the scenario, differences between the participating countries, 
specialties, sex, age categories (<50 years vs. _50 years), and years of experience 
were tested using the w2-test for categorical data. Significance level was determined 
at p<0.05. To adjust for covariance and confounding, variables with a p<0.1 in 
univariate analysis were included in a multiple logistic regression analysis. 
RESULTS  
Response rate  
In total, 8129 questionnaires were sent out to GPs and pediatricians in the five 
participating countries; 367 questionnaires were marked as not having reached their 
intended recipient (gone away, on leave, or wrong address); 2918 were completed 
and returned. (In Germany, because of a greater response rate than predicted, more 
questionnaires than in the other countries were received. Including the total number 
of received questionnaires in the data base would have resulted in a larger 
proportionate number of German pediatricians represented in the overall study 
population. This would influence overall outcomes of the total sample of 
pediatricians. 
Therefore, it was decided to randomly exclude 385 German questionnaires.). Finally, 
2533 were usable questionnaires (1176 GPs and 1357 pediatricians). Eight GPs and 
six pediatricians were then excluded as they were over the 70 years age criterion, 
leaving a dataset of 1168 GPs and 1351 pediatricians (see Table 1 for demographic 
variables of the study population). 
The total response rate was 37% (30% for GPs and 46% for pediatricians). 
Representativeness of the sample on the basis of sex and age is shown in Table 1 
(Calefato et al., 2008). 
Testing the children  
In all five countries respondents mainly agreed on testing Melanie and not testing 
Tom (see Table 2). There were significant differences between countries in 
preference for testing Melanie (w2=76.8; df=4; p<0.001), testing Catherine 
(w2=88.4; df=4; p<0.001), and testing Tom (w2=41.7; df=4; p<0.001) (see Table 2). 
It was significantly less likely for the GP or the pediatrician to test Melanie in the 
United Kingdom compared to the other countries (Germany odds ratio adjusted 
[ORadj]=4.0 [2.8–5.8]; France ORadj=2.7 [1.9–3.8]; the Netherlands ORadj=2.3 
[1.6–3.2]; Sweden ORadj=2.2 [1.6–3.1]). For Tom, he was most likely to be tested in 
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Germany compared to the other countries (Sweden ORadj=0.5 [0.4–0.6]; UK 
ORadj=0.5 [0.4–0.6]; the Netherlands ORadj= 0.7 [0.6–0.9]; France ORadj=0.8 
[NS]); particularly, pediatricians in Germany were most in favor to test Tom (see 
Table 2). 
In Germany the majority and in France practically half of the pediatricians were in 
favor of testing Catherine, whereas in the other countries (the Netherlands, Sweden, 
and the United Kingdom) the majority was in favor of not testing Catherine (see 
Table 2). 
[TABLE 1-2]  
When analyzing all countries together, there were significant differences between 
GPs and pediatricians, between men and women, and between older and younger 
physicians: GPs were less likely to test Melanie (ORadj 0.8 [0.8–0.9]) compared to 
pediatricians. Women were less likely to test Melanie (ORadj 0.8 [0.6–0.9]), but 
more likely to test Tom (ORadj 1.6 [1.3–1.9]) compared to men. Younger physicians 
(aged 24–50 years) were less likely to test Melanie, compared to their older 
colleagues (aged 51–84 years) (ORadj 0.7 [0.5–0.9]). No differences between 
specialties and age were found concerning testing Tom, or for age and sex 
concerning testing Catherine. 
Reasons for testing Melanie  
The most important reason to test Melanie (12 years) for both GPs and pediatricians 
in all countries was to plan early medical care (see Table 3). The reasons mentioned 
differed significantly between countries (w2=142.5; df=12; p<0.001). 
Most important reason not to test Melanie (12 years) was ‘‘none of the reasons 
mentioned.’’ Various other reasons was ticked mostly in this case, except for the 
Dutch GPs and the pediatricians in the United Kingdom who ticked ‘‘The child is not 
old enough to understand the medical implications’’ (w2=20.8; df=8; p=0.008) (see 
Table 3). In ticking the category ‘‘other’’ the most often explanation mentioned for 
not testing Melanie was that the respondent felt that he or she should refer to 
someone else in the medical system in this case (see Table 4). 
Testing Tom  
The most important reason for both pediatricians and GPs to test Tom (6 months) in 
all five countries was to relieve his parents’ uncertainty. The reasons mentioned for 
not testing Tom differed between countries (w2=24.3; df=8; p<0.002) (see Table 5). 
The most important reason not to test Tom (6 months) for both pediatricians and GPs 
in Germany, the United Kingdom, Sweden, and France was the feeling that no 
medical treatment is required at this age. In the Netherlands both GPs and 
pediatricians felt that Tom should not be tested because the child is not old enough to 
understand the medical implications (w2=150.0; df=8; p<0.001) (see Table 5). 
[TABLE 3]  
Testing Catherine (pediatricians scenario only) 
 Most important reason to test Catherine (8 years) in all five countries was to relieve 
her parents’ uncertainty. The reasons that were mentioned for testing Catherine 
differed and were significantly associated with country (w2=57.9; df=8; p<0.008) 
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(see Table 6). Most important reason not to test Catherine (8 years) (n=374) for 
pediatricians in France, Germany, and Sweden was the feeling that no medical 
treatment is required at this age. In the Netherlands and the United Kingdom the 
most important reason not to test Catherine was the fact that she is not old enough to 
understand the medical implications (w2=27.5; df=8; p=0.001) (see Table 6). 
DISCUSSION  
[TABLE 4-5]  
In spite of the high degree of consensus stating that ‘‘genetic testing in children is 
recommended under circumstances where a clear medical benefit to the child can be 
demonstrated’’ that exists within the many guidelines regarding genetic testing of 
minors (Ross and Moon, 2000; McConkie- Rosell and Spiridigliozzi, 2004; Borry et 
al., 2005b, 2006), no such high degree of consensus in favor of testing could be 
retrieved from the self-reported answers of the participating GPs and pediatricians. 
Our data show that this is only upheld in clinical practice for testing the oldest child 
(Melanie aged 12 years). In particular, ambiguity exists on presymptomatic genetic 
testing of young children for diseases for which medical intervention is required at 
some time during childhood, but which is not yet required or available at the time of 
the request, because of the young age of the child. 
[TABLE 6]  
 Overall, GPs and pediatricians in the five participating EU countries (France, 
Germany, the Netherlands, Sweden, and the United Kingdom) mainly agreed on 
testing Melanie aged 12 years and not testing Tom aged 6 months on their parent’s 
request after a mutation was found in the parent. However, there were differences 
between countries. It was most likely in Germany and France that the children 
become tested on the request of their affected parent, independent of their age, and 
the least likely in the United Kingdom. Particularly, pediatricians in Germany were 
more often than German GPs and physicians in the other participating countries in 
favor of testing the youngest child Tom of 6 months. 
There was a striking difference between countries concerning testing Catherine aged 
8 years. Pediatricians in France and in Germany more frequently favored testing 
Catherine, whereas in the other countries pediatricians were mainly in favor of not 
testing Catherine. One could argue that the differences found might be due to the 
differences in medical care system of the participating countries. At the time of the 
survey, in the United Kingdom and the Netherlands, for some physicians, including 
pediatricians, the standard of care would be to refer to another physician who was a 
specialist on the basis of the so-called gatekeeper system in which patients have to 
consult a primary health-care provider before access to specialists within the medical 
care system can be obtained. 
This might explain why these physicians more often ticked ‘‘no’’ if they were asked 
whether or not they were going to test the child mentioned in the questionnaire. They 
might have interpreted the question literally as if it were asked whether or not they 
themselves were going to test the child. Still, there were many physicians in these 
countries who justified their negative answer by ticking one of the reasons that were 
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already mentioned in the questionnaire (the child is not old enough to understand the 
medical implications; no medical treatment is required at this age). Thus, it remains 
unclear why physicians in France and Germany seemingly act more in line with the 
idea of medical benefit regardless its start point, which is mentioned in some of the 
existing EU guidelines (Borry, et al., 2006b), whereas physicians in Sweden, the 
Netherlands, and the United Kingdom seem to act more in line with several 
American and a Swiss guideline stating that genetic testing in minors for childhood-
onset diseases (regardless of treatment possibilities–AP) is recommended when the 
results are of ‘‘immediate’’ relevance for a child’s health (Borry et al., 2005a). 
Further, the latter might have planned to advise the parents to return to the clinic with 
the child at a later stage, to test the child at the age from which medical intervention 
actually is needed. However, this was not asked in the questionnaire. 
The reasons that were indicated by the participating physicians for or against testing 
each child questioned were also associated with each country. Particularly, the 
reasons for not testing the children differed between countries. Physicians agreed on 
testing Melanie to plan early medical care and Tom and Catherine to relieve their 
parents’ uncertainty, but they were less in agreement in justifying their negative 
answers. In some cases physicians in the Netherlands, Sweden, and the United 
Kingdom differed from those in the other countries; moreover, in some cases GPs 
differed from pediatricians. 
Especially in the case of the oldest child (Melanie aged 12 years) various reasons 
were stated why this child should not be tested: lack of knowledge, psychological 
harm, ethical issues, and impact to the family, among others, were brought up in 
justifying the negative decision. Thus, in being uncertain and lacking knowledge 
about common practice when confronted with an affected parent requesting 
presymptomatic genetic testing on a minor child for a treatable disease, the request 
will be turned down, and important preventive treatment possibilities might be 
wasted. Apparently, reasons for not testing a child are less straightforward. This 
might even be more so in a situation where one is aware that one should have acted 
otherwise, since analogous to that it was found that clinicians brought up several 
nonmedical reasons in offering predictive testing in young people for late-onset 
disorders, whereas they knew that this was not recommended (Duncan et al., 2005). 
Similar to the findings of Baars et al. (2007), who found that GPs were more 
reserved concerning genetic testing in general compared to pediatricians, GPs were 
found to be most reserved in testing the children compared to the participating 
pediatricians. This again might be due to the medical gatekeeper system in some of 
the participating countries: in those countries GPs would refer further into the 
medical system rather than testing the child personally. However, it must be taken 
into account that in this study the GPs and pediatricians were not presented with the 
same scenario and therefore a true comparison cannot be made. Still, since both 
diseases are equal in their need for early medical intervention we feel that comparing 
GPs and pediatricians at this point is permitted (Burt, 2000; Maron et al., 2003). 
Further, there were differences between male and female physicians and older and 
younger physicians. The older physicians were more often in favor of testing the 
children. 
This is consistent with the finding elsewhere that older, and more experienced GPs, 
gynecologists=obstetricians, and pediatricians were most innovative in offering 
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genetic testing (Baars et al., 2007). There was a remarkable difference within the 
group women and their preference for testing Melanie and Tom. Contrary to male 
physicians they were more in favor of testing Tom and less in favor of testing 
Melanie. We cannot think of any plausible explanation why this occurred. Moreover, 
no differences between male and female students were found in a study in which 
students’ decision on whether or not to genetically test a minor was being examined 
(Riordan and Loescher, 2006). This decision did depend on the disease presented, on 
the age of the minor, but also on the amount of GenEd the students had had during 
their years of education: the more GenEd, the less prone they were to test the 
youngest child (at the age of 7), but sex differences did not occur. 
Despite the large number of physicians that were found to be in favor of testing at 
least one of the children, these findings are still not in line with the general 
recommendation that children should undergo presymptomatic diagnostic genetic 
testing if the disorder concerned is treatable and early medical intervention desirable. 
However, it can be discussed whether or not it should be recommended to test Tom 
already at the age of 6 months, since medical treatment is not required at his age for 
both FAP and HCM. Testing Tom could be postponed till the time medical treatment 
is required. More clarity of when this time has come and thus a clear definition of the 
age at which genetic presymptomatic testing of the child ideally should be carried 
out, preferably related to specific diseases, is therefore needed. One might even 
consider stressing the medical benefits in cases of presymptomatic testing of minors 
for a treatable disease, over psychological benefit (or harm). 
More in general, it could be recommended that minors should not be tested before 
medical intervention (see also www .eshg.org for proposed recommendations on this 
issue). This might facilitate the utility of the existing guidelines in daily health-care 
practice and optimize patient care. The balance between the psychological benefits or 
harm should strongly be considered in cases of genetic testing for nontreatable 
diseases or when carrier testing is concerned. 
Limitations of the study  
In some of the participating countries the GPs do have the role of gatekeeper; in 
other countries they do not. Due to these differences in health-care systems, some 
physicians might have interpreted the question literally that was posed about testing 
the child. 
The scenario that was presented in the questionnaire was more applicable to GPs and 
pediatricians in some countries compared to others. In those countries were it was 
difficult for physicians to imagine that this problem would be presented to them in 
their daily practice, they might have decided more negatively than they otherwise 
would have. 
To not lose comparability of the data gathered between countries and specialties, and 
to achieve a representative sample based on power analysis, it was decided only to 
include the first 250 filled-out questionnaires returned for each specialty in each 
country. In some countries or with regard to some specialties, particularly primary 
health care, it is known that it is difficult to achieve high response rates (Robertson et 
al., 2005; Keating et al., 2008). The response rate of for pediatricians is slightly 
below average in large studies, but that of GPs is low (Robertson et al., 2005). 
Nevertheless, we feel that this is a useful sample. Moreover, there is no necessary 
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relationship between response rate and bias: surveys with low response rates might 
provide a representative sample of the population of interest (Robertson et al., 2005). 
Finally, the study findings in some areas could be biased to physicians who hold 
more extreme views or who were interested in the subject of genetics. 
CONCLUSION  
It is of great importance to formulate a standard unambiguous guideline on genetic 
testing on minors, within the European Union, to create more clarity on when 
children should be tested for treatable diseases: immediately, regardless of age, or 
should it be postponed until the age at which medical intervention is actual available, 
to plan early medical care. This will optimize patient care and prevent important 
preventive treatment possibilities from being wasted. 
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APPENDIX: SCENARIOS 
 GP scenario: sudden death  
Mr. Smith (aged 35 years) attends your surgery because his 27-year-old brother, a 
competitive swimmer, has just died suddenly. He collapsed in the pool and died 
despite defibrillation. 
Although sudden death might not immediately suggest a genetic condition, Mr. 
Smith is worried because his mother’s sister died suddenly aged 30 years and asks 
whether the same may happen to him or his children Melanie (12 years) and Tom (6 
months). 
He has been told that his brother’s postmortem demonstrated hypertrophic 
cardiomyopathy, which can be inherited as an autosomal dominant condition. Eighty 
percent of nontraumatic sudden deaths in young athletes are due to inherited or 
congenital cardiovascular abnormalities, and hypertrophic cardiomyopathy accounts 
for 40–50% of these. Genetic testing may lead to identification of patients at high 
risk for sudden death as early as 10 years of age. Treatment can be considered with 
medication or implantable defibrillators. 
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Pediatric scenario: familial adenomatous polyposis scenario  
Mrs. Ogilvie (aged 31 years), a mother of three children, Melanie (12 years), 
Catherine (8 years), and Tom (6 months), attends your clinic. Mrs. Ogilvie has a 
family history of colon cancer. Her father died at 42 years of age with colon cancer 
(no histology report available). Mrs. Ogilvie recently had a colectomy when she 
presented with rectal bleeding shortly after Tom’s birth. The presence of hundreds of 
polyps was consistent with a diagnosis of typical familial adenomatous polyposis, an 
autosomal dominant condition. 
She has been discharged from surgical services. Mrs. 
Ogilvie has come to terms with the diagnosis, but she is now worried about the 
genetic risk for her children. If a gene mutation for typical familial adenomatous 
polyposis can be found in Mrs. Ogilvie’s family, presymptomatic testing will be 
possible. Polyps can appear in the bowel between 12 and 25 years of age. It is very 
unusual to develop colon cancer as early as 8 years.    
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